Safety and immunogenicity of plant-produced African horse sickness virus-like particles in horses.
Abstract: African horse sickness (AHS) is caused by multiple serotypes of the dsRNA AHSV and is a major scourge of domestic equids in Africa. While there are well established commercial live attenuated vaccines produced in South Africa, risks associated with these have encouraged attempts to develop new and safer recombinant vaccines. Previously, we reported on the immunogenicity of a plant-produced AHS serotype 5 virus-like particle (VLP) vaccine, which stimulated high titres of AHS serotype 5-specific neutralizing antibodies in guinea pigs. Here, we report a similar response to the vaccine in horses. This is the first report demonstrating the safety and immunogenicity of plant-produced AHS VLPs in horses.
Publication Date: 2018-10-11 PubMed ID: 30309390PubMed Central: PMC6389048DOI: 10.1186/s13567-018-0600-4Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research study examines the safety and efficacy of a new type of vaccine made from plants for African horse sickness, a deadly disease affecting horses in Africa. This new vaccine was found to be safe and able to induce a strong immune response in horses.
Research Objective and Context
- The goal of this research was to determine the safety and ability to trigger an immune response (immunogenicity) of a new type of preventative measure against African horse sickness (AHS). AHS is caused by a virus (AHSV) and is a significant threat to domestic horse populations in Africa.
- Although vaccines for AHS exist and are commercially available, they carry various risks due to their live attenuated state (a live virus that has been weakened, but could still present risk). The research team aimed to develop a safer vaccine using a recombinant technique.
- The new vaccine is based on Virus-like particles (VLPs) for AHS serotype 5 and was produced using plants. This is a novel method and differs significantly from traditionally produced vaccines.
Methodology and Findings
- The vaccine’s effectiveness had previously been tested on guinea pigs, where it was shown to stimulate a high level of AHS serotype 5-specific neutralizing antibodies, meaning it triggered the animals’ immune response to effectively neutralise the virus.
- In this research, the team expanded their testing to horses. Similar to the guinea pigs’ response, the horses showed a robust immune response, suggesting the vaccine’s effectiveness can be translated to the species it was originally designed to protect.
- Importantly, the vaccine was found to be safe to use in horses, an equally crucial factor in any new vaccine’s potential viability.
Implications
- This research represents the first report on the safety and immunogenicity of a plant-produced AHS vaccine in horses. It shows that plant-produced VLPs could be a viable alternative to live attenuated vaccines for AHS.
- The study could pave the way for further research into plant-produced vaccines for other animal diseases. A successful implementation could potentially lead to more secure and flexible vaccine production processes.
Cite This Article
APA
Dennis SJ, O'Kennedy MM, Rutkowska D, Tsekoa T, Lourens CW, Hitzeroth II, Meyers AE, Rybicki EP.
(2018).
Safety and immunogenicity of plant-produced African horse sickness virus-like particles in horses.
Vet Res, 49(1), 105.
https://doi.org/10.1186/s13567-018-0600-4 Publication
Researcher Affiliations
- Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Rondebosch, Cape Town, 7701, South Africa.
- Council for Scientific and Industrial Research (CSIR) Biosciences, Pretoria, 0001, South Africa.
- Council for Scientific and Industrial Research (CSIR) Biosciences, Pretoria, 0001, South Africa.
- Council for Scientific and Industrial Research (CSIR) Biosciences, Pretoria, 0001, South Africa.
- Department of Veterinary Tropical Diseases, Faculty of Veterinary Sciences, University of Pretoria, Onderstepoort, Pretoria, 0110, South Africa.
- Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Rondebosch, Cape Town, 7701, South Africa.
- Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Rondebosch, Cape Town, 7701, South Africa. ann.meyers@uct.ac.za.
- Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Rondebosch, Cape Town, 7701, South Africa.
- Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, 7925, South Africa.
MeSH Terms
- African Horse Sickness / prevention & control
- African Horse Sickness Virus
- Animals
- Antibodies, Neutralizing / immunology
- Antibodies, Viral / immunology
- Horses
- Nicotiana / metabolism
- Vaccines, Attenuated / immunology
- Viral Vaccines / immunology
Grant Funding
- TAHIC13-00023-CC / South African Technology Innovation Agency
References
This article includes 16 references
- Coetzer JAW, Guthrie AJ. African horse sickness. .
- Mellor PS, Hamblin C. African horse sickness. Vet Res 2004;35:445–466.
- Alexander RA. The immunization of horses and mules against horse sickness by means of the neurotropic virus of mice and guinea-pigs. Onderstepoort J Vet Sci Anim Ind 1934;2:375–391.
- Weyer CT, Grewar JD, Burger P, Rossouw E, Lourens C, Joone C, le Grange M, Coetzee P, Venter E, Martin DP, MacLachlan NJ, Guthrie AJ. African horse sickness caused by genome reassortment and reversion to virulence of live, attenuated vaccine viruses, South Africa, 2004–2014. Emerg Infect Dis 2016;22:2087–2096.
- Guthrie AJ, Quan M, Lourens CW, Audonnet JC, Minke JM, Yao J, He L, Nordgren R, Gardner IA, Maclachlan NJ. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus. Vaccine 2009;27:4434–4438.
- Manning NM, Bachanek-Bankowska K, Mertens PPC, Castillo-Olivares J. Vaccination with recombinant modified vaccinia ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination. Vaccine 2017;35:6024–6029.
- Lulla V, Losada A, Lecollinet S, Kerviel A, Lilin T, Sailleau C, Beck C, Zientara S, Roy P. Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge. Vaccine 2017;35:4262–4269.
- van Rijn PA, Maris-Veldhuis MA, Potgieter CA, van Gennip RGP. African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS disabled infectious single animal (DISA) vaccine platform. Vaccine 2018;36:1925–1933.
- Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol 2003;11:438–444.
- Dennis SJ, Meyers AE, Guthrie AJ, Hitzeroth II, Rybicki EP. Immunogenicity of plant-produced African horse sickness virus-like particles: implications for a novel vaccine. Plant Biotechnol J 2018;16:442–450.
- Sainsbury F, Thuenemann EC, Lomonossoff GP. pEAQ: versatile expression vectors for easy and quick transient expression of heterologous proteins in plants. Plant Biotechnol J 2009;7:682–693.
- Chuma T, Le Blois H, Sanchez-Vizcaino JM, Diaz-Laviada M, Roy P. Expression of the major core antigen VP7 of African horsesickness virus by a recombinant baculovirus and its use as a group-specific diagnostic reagent. J Gen Virol 1992;73:925–931.
- Bekker S, Burger P, van Staden V. Analysis of the three-dimensional structure of the African horse sickness virus VP7 trimer by homology modelling. Virus Res 2017;232:80–95.
- von Teichman BF, Dungu B, Smit TK. In vivo cross-protection to African horse sickness serotypes 5 and 9 after vaccination with serotypes 8 and 6. Vaccine 2010;28:6505–6517.
- Weyer CT, Grewar JD, Burger P, Joone C, Lourens C, MacLachlan NJ, Guthrie AJ. Dynamics of African horse sickness virus nucleic acid and antibody in horses following immunization with a commercial polyvalent live attenuated vaccine. Vaccine 2017;35:2504–2510.
- Crafford JE, Lourens CW, Smit TK, Gardner IA, MacLachlan NJ, Guthrie AJ. Serological response of foals to polyvalent and monovalent live-attenuated African horse sickness virus vaccines. Vaccine 2014;32:3611–3616.
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
